Table 2.
Comparison of general population information and clinical data between the NAFLD group and non-NAFLD group
| NAFLD group (n=100)
|
Non-NAFLD group (n=102)
|
χ2 | df | P-value | |||
|---|---|---|---|---|---|---|---|
| n | % | n | % | ||||
| History of smoking Antipsychotics | 22 | 22.0 | 18 | 17.6 | 0.6 | 1 | 0.483 |
| Medication combination | 63 | 63.0 | 37 | 36.3 | 14.4 | 1 | 0.000 |
| Drug doses (CPZ) | 15.0 | 2 | 0.001 | ||||
| <300 mg | 5 | 5.0 | 18 | 17.6 | |||
| 300–600 mg | 29 | 26.0 | 39 | 38.2 | |||
| .600 mg | 69 | 69.0 | 45 | 44.1 | |||
|
|
|
|
|||||
| Mean | SD | Mean | SD | T | df | P-value | |
|
|
|
|
|||||
| Age (years) | 30.5 | 3.8 | 30.5 | 4.0 | 0.09 | 200 | 0.929 |
| Disease duration (year) | 7.1 | 4.0 | 5.6 | 5.3 | 2.31 | 200 | 0.022 |
| PANSS | 49.5 | 11.4 | 50.3 | 14.1 | −0.48 | 200 | 0.629 |
| PANSS positive factors | 11.9 | 4.7 | 13.1 | 5.5 | −1.62 | 200 | 0.107 |
| PANSS negative factors | 14.1 | 4.0 | 12.7 | 4.5 | 2.35 | 200 | 0.020 |
| BMI | 24.1 | 3.9 | 21.9 | 3.7 | 4.52 | 200 | 0.000 |
| Systolic pressure | 126.8 | 9.6 | 126.6 | 9.4 | 0.17 | 200 | 0.863 |
| Diastolic pressure | 73.5 | 6.1 | 74.0 | 6.7 | −0.52 | 200 | 0.602 |
| Fasting blood glucose | 5.3 | 1.4 | 4.7 | 0.9 | 3.51 | 200 | 0.001 |
| Total cholesterol | 5.2 | 1.3 | 4.9 | 1.1 | 2.13 | 200 | 0.034 |
| Triglyceride | 2.8 | 1.5 | 1.8 | 1.4 | 5.10 | 200 | 0.000 |
| ALT | 44.3 | 24.2 | 33.2 | 20.4 | 3.54 | 200 | 0.001 |
| AST | 30.9 | 13.8 | 24.4 | 9.8 | 3.86 | 200 | 0.000 |
| ALP | 64.9 | 16.9 | 63.8 | 16.1 | 0.45 | 200 | 0.654 |
| GGT | 53.7 | 20.9 | 46.0 | 35.6 | 0.86 | 200 | 0.065 |
Abbreviations: ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; NAFLD, nonalcoholic fatty liver disease; CPZ, chlorpromazine; PANSS, Positive and Negative Syndrome Scale; BMI, body mass index.